Loading
ETS1 (ETS proto-oncogene 1, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Transcription factor. Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · ETS1 (ETS proto-oncogene 1, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
ETS1 (ETS proto-oncogene 1, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Diffuse large B-cell lymphoma.
Transcription factor. Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts.
No product in this corpus aims at ETS1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ETS1: RNA tissue enhanced (lymphoid tissue 253 nTPM); high antibody staining in 4 normal tissues; highest cancer staining lymphoma (5 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lymphoma); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas ETS1 tissue; Open Targets ENSG00000134954 associations
First described 1985. Earliest sequence paper UniProt cites for the protein: Watson D.K. et al, Proc. Natl. Acad. Sci. U.S.A, 1985, "The ets sequence from the transforming gene of avian erythroblastosis virus, E26, has unique domains on human chromosomes 11 and 21: both loci are transcriptionally active". Source.
Sources: HGNC HGNC:3488 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P14921 (protein name, function text, keywords and locations (REST API)); CIViC gene ETS1 (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0))
Transcription factor. Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells. May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion. Acts as a dominant-negative for isoform c-ETS-1A. Location: Nucleus; Cytoplasm (UniProt). Locus 11q24.3 (HGNC).
RNA: tissue enhanced (lymphoid tissue 253 nTPM), detected in all normal tissues.
Medium: Spleen.
Medium only: lung cancer, melanoma, urothelial cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ETS1" OR ABSTRACT:"ETS1" OR TITLE:"ETS proto-oncogene 1, transcription factor" OR ABSTRACT:"ETS proto-oncogene 1, transcription factor" OR TITLE:"FLJ10768" OR ABSTRACT:"FLJ10768" OR TITLE:"ETS-1" OR ABSTRACT:"ETS-1" OR TITLE:"EWSR2" OR ABSTRACT:"EWSR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ETS1, not a curated reading list.